Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and TENS for Self-Injurious Behavior
NCT00065936Phase 3Unknown
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Start
- Jul 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of naltrexone in Self-injurious behavior (3 arms), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoints: Frequency of self-injurious behavior at 16 weeks, Duration of self-injurious behavior at 16 weeks and 1 more. Status: unknown.
02
Drugs
naltrexone
03
Conditions
Self-injurious behavior
Beyond the preview
Go deeper on NCT00065936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065936.